Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Laflamme

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Health Affairs (Project Hope)|January 12, 2010
Preterm births: a better comparison statisticDavid Laflamme
International Journal of Clinical Practice|January 15, 2021
Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) ProgrammeKori Leblanc, Alan D Bell, Justin A Ezekowitz, et al.
International Journal of Clinical Practice|July 6, 2021
Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) studySanam Verma, Shaun G Goodman, Mary K Tan, et al.
Nature Medicine|January 7, 2026
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trialLéna Rivard, Paul Khairy, Mario Talajic, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Health Affairs (Project Hope)|January 12, 2010
Preterm births: a better comparison statisticDavid Laflamme
International Journal of Clinical Practice|January 15, 2021
Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) ProgrammeKori Leblanc, Alan D Bell, Justin A Ezekowitz, et al.
International Journal of Clinical Practice|July 6, 2021
Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) studySanam Verma, Shaun G Goodman, Mary K Tan, et al.
Nature Medicine|January 7, 2026
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trialLéna Rivard, Paul Khairy, Mario Talajic, et al.
Pageof 1